DongKoo Bio & Pharma Co. Ltd. Cash Flow Quality Index
DongKoo Bio & Pharma Co. Ltd. cash flow quality index. DongKoo Bio & Pharma Co. Ltd. (006620) has a Cash Flow Quality Index of 0.12x as of December 2025. Operating cash flow of ₩5.15 Billion is below net income of ₩41.27 Billion, suggesting accrual-heavy earnings not yet converted to cash. See DongKoo Bio & Pharma Co. Ltd. leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of DongKoo Bio & Pharma Co. Ltd. (2015–2025)
Cash flow quality index of DongKoo Bio & Pharma Co. Ltd. from 2015 to 2025. Historical Cash Flow Quality Index for DongKoo Bio & Pharma Co. Ltd. across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore 006620 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
DongKoo Bio & Pharma Co. Ltd. Cash Flow Quality Index by Year (2015–2025)
DongKoo Bio & Pharma Co. Ltd. cash flow quality index by year from 2015 to 2025. Year-by-year earnings quality comparison for DongKoo Bio & Pharma Co. Ltd.. For the full cash flow conversion analysis, see 006620 cash generation efficiency.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -0.09x | ₩-4.29 Billion | ₩50.27 Billion | ▼ -101.0% |
| 2024 | 8.71x | ₩17.34 Billion | ₩1.99 Billion | ▲ +2769.4% |
| 2023 | 0.30x | ₩3.59 Billion | ₩11.81 Billion | ▼ -88.1% |
| 2022 | 2.54x | ₩16.82 Billion | ₩6.61 Billion | ▲ +32.5% |
| 2021 | 1.92x | ₩17.90 Billion | ₩9.33 Billion | ▲ +134.3% |
| 2020 | 0.82x | ₩7.49 Billion | ₩9.14 Billion | ▲ +22.0% |
| 2019 | 0.67x | ₩10.14 Billion | ₩15.10 Billion | ▲ +487.8% |
| 2018 | -0.17x | ₩-791.20 Million | ₩4.57 Billion | ▼ -119.9% |
| 2017 | 0.87x | ₩9.51 Billion | ₩10.94 Billion | ▼ -24.7% |
| 2016 | 1.15x | ₩12.59 Billion | ₩10.91 Billion | ▼ -33.0% |
| 2015 | 1.72x | ₩6.93 Billion | ₩4.03 Billion | — |